Skip to main content

Table 1 Correlation with pCR (univariate logistic regression analysis)

From: Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

 

n

events

% pCR

OR

95% CI

p

age (per year)

116

13

-

0.96

0.90-1.01

0.128

biology-based tumor type

116

13

   

0.044a

   HR+/HER2-

57

1

1.8

1.00

  

   HR+/HER2+

13

3

23.1

16.80

1.59-178.12

0.019

   HR-/HER2+

13

1

7.7

4.67

0.27-79.96

0.288

   HR-/HER2-

33

8

24.2

17.92

2.13-151.04

0.008

Ki67

106

12

    

   <= 20%

85

5

5.9

1.00

  

   > 20%

21

7

33.3

8.00

2.22-28.79

0.001

CK5/6

114

13

    

   negative

107

10

9.3

1.00

  

   positive

7

3

42.9

7.28

1.42-37.22

0.017

COX-2

101

12

    

   negative

27

5

18.5

1.00

  

   positive

74

7

9.5

0.46

0.13-1.60

0.221

YB-1

106

12

    

   negative

71

8

11.3

1.00

  

   positive

35

4

11.4

1.02

0.28-3.36

0.980

therapy arm

116

13

    

   ddADOC

61

3

4.9

1.00

  

   AC-DOC

55

10

18.2

4.30

1.12-16.53

0.034

histology

116

13

   

0.767a

   ductal-invasive

98

12

12.2

1.00

  

   lobular

14

0

0.0

0.00

0.00- -

0.999

   others

4

1

25.0

2.39

0.23-24.86

0.466

grade

116

13

    

   G1-2

76

3

3.9

1.00

  

   G3

40

10

25.0

8.11

2.09-31.55

0.003

cT

116

27

   

0.570a

   cT1

9

2

22.2

1.00

  

   cT2

87

9

10.3

0.40

0.07-2.25

0.300

   cT3

20

2

10.0

0.39

0.05-3.32

0.388

cN

116

27

    

   cN0

79

8

10.1

1.00

  

   cN1-2

37

5

13.5

1.39

0.42-4.57

0.591

  1. OR: odds ratio; CI: confidence interval;a: overall significance.